Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0031 | 0 | 0.5 | |
Chlamydia trachomatis | triosephosphate isomerase | 0.0313 | 1 | 0.5 |
Schistosoma mansoni | triosephosphate isomerase | 0.0313 | 1 | 1 |
Onchocerca volvulus | 0.0031 | 0 | 0.5 | |
Trypanosoma brucei | triosephosphate isomerase | 0.0313 | 1 | 1 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0313 | 1 | 1 |
Onchocerca volvulus | 0.0031 | 0 | 0.5 | |
Onchocerca volvulus | 0.0031 | 0 | 0.5 | |
Mycobacterium leprae | Probable triosephosphate isomerase Tpi (TIM) | 0.0313 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 0.6164 | 0.6164 |
Echinococcus granulosus | geminin | 0.0205 | 0.6164 | 0.6164 |
Echinococcus granulosus | triosephosphate isomerase | 0.0313 | 1 | 1 |
Onchocerca volvulus | 0.0031 | 0 | 0.5 | |
Wolbachia endosymbiont of Brugia malayi | triosephosphate isomerase | 0.0313 | 1 | 0.5 |
Plasmodium falciparum | triosephosphate isomerase | 0.0313 | 1 | 1 |
Toxoplasma gondii | triose-phosphate isomerase TPI-I | 0.0313 | 1 | 1 |
Loa Loa (eye worm) | triosephosphate isomerase | 0.0313 | 1 | 1 |
Leishmania major | triosephosphate isomerase | 0.0313 | 1 | 1 |
Trypanosoma cruzi | triosephosphate isomerase, putative | 0.0313 | 1 | 1 |
Echinococcus multilocularis | triosephosphate isomerase | 0.0313 | 1 | 1 |
Onchocerca volvulus | 0.0031 | 0 | 0.5 | |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0313 | 1 | 1 |
Toxoplasma gondii | triose-phosphate isomerase TPI-II | 0.0313 | 1 | 1 |
Mycobacterium ulcerans | triosephosphate isomerase | 0.0313 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.6164 | 0.6164 |
Giardia lamblia | Triosephosphate isomerase, cytosolic | 0.0313 | 1 | 1 |
Treponema pallidum | triosephosphate isomerase | 0.0313 | 1 | 0.5 |
Entamoeba histolytica | triosephosphate isomerase | 0.0313 | 1 | 1 |
Mycobacterium tuberculosis | Probable triosephosphate isomerase Tpi (TIM) | 0.0313 | 1 | 1 |
Schistosoma mansoni | triosephosphate isomerase | 0.0127 | 0.34 | 0.34 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0313 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.6164 | 0.6164 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.